Medical/Pharmaceuticals
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
* Transition from An Asset-Heavy Business Model to An Asset-Light Business Model * Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible * Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Rose by 120% Year-over-Year * Total Marketpla...
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG, Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluatio...
Tianjin University Leads World's 1st ISO Standard for Single-Herb TCM Formula Granules
TIANJIN, China, Sept. 16, 2026 /PRNewswire/ -- The International Organization for Standardization (ISO) has published ISO 21756:2026, the world's first international standard for single-herb Traditional Chinese Medicine (TCM) formula granules. Titled Traditional Chinese Medicine —Salvia miltiorrh...
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
* Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to re...
Datasea Expands into China's Trillion-RMB Silver Economy Through Strategic Cooperation in AI Elderly Care Robots
Datasea plans to combine its AI agent and digital platform capabilities with its partner's robotics technologies and elderly care deployment experience to develop intelligent care solutions for China's rapidly growing silver economy BEIJING, Sept. 16, 2026 /PRNewswire/ -- Datasea Intelligent Tech...
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
* Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United
States (NCT06635785
LANDMARK GLOBAL STUDY REVEALS CRITICAL INEQUITIES IN ACCESS TO DERMATOLOGICAL CARE
First comprehensive global assessment by the International League of
Dermatological Societies (ILDS) and L'Oréal Dermatological Beauty spans 158
countries and 97% of the world's population.
Summary: The Global Access to Skin Health Observatory Study
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
SHANGHAI, Sept. 16, 2026 /PRNewswire/ -- Forbes China recently released the 2026 Forbes China ESG 50 list. WuXi Biologics was named to the list for its outstanding performance in sustainable development, Green CRDMO solutions and ESG digital innovation, and was highlighted by Forbes China as one ...
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks
* Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) * Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks in adults and launched in over 30 countries worldwide * Authorization supported by the Pha...
GHIT Fund Launches "NTDpedia" to Help Turn Apathy Into Action Against Neglected Tropical Diseases
The interactive educational website makes NTDs understandable to a general audience, the first step toward public support that drives R&D for the 1.5 billion people affected by these diseases TOKYO, Sept. 16, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced the ...
Ferronova announces preliminary results of MAGMAP, a 62-patient gastric and oesophageal cancer trial investigating lymph node mapping
KYOTO, Japan, Sept. 16, 2026 /PRNewswire/ -- Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesophageal patients evaluating the safety and feasibility of a new nanoparticle-based platform to assist cl...
Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients
* The fifteen-month dataset represents the final analysis from the Phase 1/2 study * At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington's Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted extern...
CordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of Growth
* Dr. Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026 * Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma * Planned leadership transition builds on 12 ye...
Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society
* Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program committee determines to be of immediate importance to the field * Presentation expected to provide the first clinical evidence that a small activating RNA (saRNA) can u...
Natus Launches Locally Manufactured Nicolet EDX System in China
SUZHOU, China, Sept. 15, 2026 /PRNewswire/ -- Natus Medical Incorporated, the
world's largest pure-play neurodiagnostic company, today announced the launch
of the Nicolet EDX EMG system in the People's Republic of China, marking the
first Natus product manufactured and sold in the PRC.
Totaria Highlights Magnesium Nutrition Awareness During Healthy Aging Month
AURORA, Colo., Sept. 15, 2026 /PRNewswire/ -- As September marks Healthy Aging
Month
Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder
BOSTON, Sept. 15, 2026 /PRNewswire/ -- Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, today announced the first participants dosed in its Phase 1 clinical study of XYL-1001, a novel, selective 5-HT2A agonist being de...
RIGHT CARE, RIGHT PLACE: NUHS MARKS A DECADE OF ADVANCING VALUE-BASED CARE, SAVING 18,225 BED DAYS
The NUHS Appropriate and Value-Based Care Symposium 2026 showcases a decade of proven impact — providing value-based care to over 300,000 patients, saving 18,225 bed days, and advancing a model for healthcare transformation across Singapore SINGAPORE, Sept. 15, 2026 /PRNewswire/ -- More than 300...
Honda Prize 2026 Awarded to Professor Graeme M. Clark and Dr. Ingeborg Hochmair
- For Spearheading Research and Development, Clinical Application and Worldwide Adoption of Multichannel Cochlear Implant - TOKYO, Sept. 15, 2026 /PRNewswire/ -- The Honda Foundation has selected Professor Graeme M. Clark AC, an Australian medical doctor and neuroscientist and laureate professor...
Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026
HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organ...
Week's Top Stories
Most Reposted
BoomerangFX Launches ChatGPT AI Search Advertising for Aesthetic, Wellness and Private-Pay Healthcare Practices, Powered by AUVIA™ AI Clinic Co-Pilot
[Picked up by 1315 media titles]
2026-11-17 23:03Manulife announces Subordinated Debenture issue
[Picked up by 1205 media titles]
2026-11-17 06:45vVardis Raises $175 Million Ahead of NYSE IPO: NYSE Content Update
[Picked up by 1188 media titles]
2026-11-13 22:11The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1176 media titles]
2026-11-14 13:23Cision Introduces AI-Powered Cision Intelligence to Help Brands See More and Act with Confidence
[Picked up by 1172 media titles]
2026-11-12 23:00